Garry Menzel, PhD and MBA

Dr. Menzel joined TCR² in 2016 as a Director and Chief Executive Officer. He has over 25 years of experience in building healthcare businesses and leading high-performing teams of professionals. His versatile career has included operational roles covering drug development, manufacturing, financing, licensing and M&A. Prior to TCR², he was the Chief Strategy Officer at Axcella Health (NASDAQ:AXLA), the Chief Financial Officer at DaVita Healthcare (NYSE:DVA), and the Chief Operating Officer at Regulus Therapeutics (NASDAQ:RGLS). Dr. Menzel also had global leadership roles in running the biotechnology practices at Goldman Sachs and Credit Suisse where he advised on more than $100 billion in strategic transactions. In addition, he was a consultant with Bain & Company. Dr. Menzel has also served on the board of directors of the oncology company Black Diamond Therapeutics Inc. since 2014 and is the Chair of the Audit Committee. He earned his PhD from the University of Cambridge for studying the regulation of oncogenes in immune cells. He also has a MBA from the Stanford Graduate School of Business.